Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors

Introduction: Although tyrosine kinase inhibitors (TKIs) are effective against NSCLC harboring sensitizing EGFR gene mutations, acquired resistance is inevitable. Preclinical studies suggest that combining EGFR TKI and monoclonal antibody therapies may have activity in EGFR-mutated NSCLC that has pr...

Täydet tiedot

Tallennettuna:

Bibliografiset tiedot
Päätekijät:	Nathaniel J. Myall, MD, Jennifer G. Whisenant, PhD, Joel W. Neal, MD, PhD, Wade T. Iams, MD, Karen L. Reckamp, MD, Sally York, MD, PhD, Lynne D. Berry, PhD, Yu Shyr, PhD, Leora Horn, MD, Heather A. Wakelee, MD, Sukhmani K. Padda, MD
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2025-02-01
Sarja:	JTO Clinical and Research Reports
Aiheet:	Dual EGFR inhibition Phase I trial Lung cancer EGFR-mutated
Linkit:	http://www.sciencedirect.com/science/article/pii/S2666364324001279
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors

Samankaltaisia teoksia